Founded as a spin-off from Sweden’s Chalmers University of Technology, Fluicell made a big entry into the 3D bioprinting market in 2019 with the launch of its Biopixlar platform. Today, the company is preparing to expand its system offering with the launch of a new machine, the Biopixlar AER. The bioprinter, which will become available on March 3, 2022, is based on the same single-cell high-resolution bioprinting technology as the original Biopixlar but offers advances in automation and is more compact.
The new Biopixlar AER is a portable microfluidic bioprinting system, and Fluicell has specifically designed the compact system to fit inside standard cell culture flow hoods. This will enable researchers to more easily use Fluicell’s single-cell bioprinting technology in combination with other in vitro and 3D cell culture technologies. According to the Swedish bioprinting company, its system is the first of its kind to be designed in such a way.
In addition to size, Fluicell has prioritized automation in developing its latest bioprinting system. The new machine introduces various process automation features to streamline research workflows. The bioprinter also integrates remote control. The combination of portability and enhanced automation make the Biopixlar AER suitable for demanding applications in areas like medicine, aerospace and deep-sea exploration.
“Biopixlar AER is truly a breakthrough technological achievement, representing a product offering perfectly in line with our overall aspiration and ethos to join biology and technology in order to meet future healthcare needs,” says Fluicell CEO Victoire Viannay. “Biopixlar AER fits perfectly into Fluicell’s strategy to make a difference for researchers by increasing the flexibility, performance and adaptability in bioprinting. Biopixlar AER is also targeting new customer segments that emphasize the ability to parallelize and automate bioprinting and cell culture processes.”
Gavin Jeffries, Fluicell CTO, adds: “The Biopixlar AER marks a milestone for Fluicell, delivering portable fluidic bioprinting capabilities into conventional researcher workflows. This new platform within the Biopixlar family comes as a result of focusing on user needs and anticipating future demands within the rapidly accelerated bio-engineering sector. The AER showcases a wide range of powerful features tailored for today’s laboratory environment. A deep integration of fluidic, optical and motion control, combined with a small footprint and process automation, is designed to empowers researchers with bioprinting tools in demanding environments. The growing knowledge and needs within the bioprinting field requires platforms to be tailored for both current and future research. This expansion to the Biopixlar family, delivers on this opportunity.”
With its original bioprinter, the Biopixlar, Fluicell introduced a new approach to bioprinting. That is, the system was the first to utilize single-cell bioprinting, which positions cells in three dimensions without the use of a bioink. This technology has the advantage of maintaining cells in their native environment and printing structures with single-cell resolution. The Biopixlar AER is based on this same technology.